Cargando…
BioBanking - The Holy Grail of novel drug and diagnostic developments?
The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobank...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164607/ https://www.ncbi.nlm.nih.gov/pubmed/21884630 http://dx.doi.org/10.1186/2043-9113-1-14 |
_version_ | 1782211051493785600 |
---|---|
author | Marko-Varga, György |
author_facet | Marko-Varga, György |
author_sort | Marko-Varga, György |
collection | PubMed |
description | The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobanks are becoming the new powerful modality within the field of modern Life Science, that is expected to be important in the proactive awareness of patient health status. Biobanks are also expected to promote the developments of targeted treatments with personalized indicator assays, for effective use of Personalized Medicine treatments in the near future. |
format | Online Article Text |
id | pubmed-3164607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31646072011-09-02 BioBanking - The Holy Grail of novel drug and diagnostic developments? Marko-Varga, György J Clin Bioinforma Editorial The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobanks are becoming the new powerful modality within the field of modern Life Science, that is expected to be important in the proactive awareness of patient health status. Biobanks are also expected to promote the developments of targeted treatments with personalized indicator assays, for effective use of Personalized Medicine treatments in the near future. BioMed Central 2011-05-13 /pmc/articles/PMC3164607/ /pubmed/21884630 http://dx.doi.org/10.1186/2043-9113-1-14 Text en Copyright ©2011 Marko-Varga; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editorial Marko-Varga, György BioBanking - The Holy Grail of novel drug and diagnostic developments? |
title | BioBanking - The Holy Grail of novel drug and diagnostic developments? |
title_full | BioBanking - The Holy Grail of novel drug and diagnostic developments? |
title_fullStr | BioBanking - The Holy Grail of novel drug and diagnostic developments? |
title_full_unstemmed | BioBanking - The Holy Grail of novel drug and diagnostic developments? |
title_short | BioBanking - The Holy Grail of novel drug and diagnostic developments? |
title_sort | biobanking - the holy grail of novel drug and diagnostic developments? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164607/ https://www.ncbi.nlm.nih.gov/pubmed/21884630 http://dx.doi.org/10.1186/2043-9113-1-14 |
work_keys_str_mv | AT markovargagyorgy biobankingtheholygrailofnoveldruganddiagnosticdevelopments |